CAJ | 학술논문

B细胞淋巴瘤的预后在利妥昔单抗出现之后有了明显改善,但仍有一部分患者会复发进展.嵌合抗原受体T细胞(CAR T细胞)是通过基因修饰的方法获得的针对肿瘤细胞表面特定抗原的特异性T细胞,在复发难治B细胞淋巴瘤的治疗中取得了很好疗效,目前研究最多的是针对B细胞淋巴瘤表面的CD19抗原.文章综述了抗CD19 CAR T细胞在复发难治B细胞淋巴瘤中的疗效、不良反应及目前存在的问题.
B세포림파류적예후재리타석단항출현지후유료명현개선,단잉유일부분환자회복발진전.감합항원수체T세포(CAR T세포)시통과기인수식적방법획득적침대종류세포표면특정항원적특이성T세포,재복발난치B세포림파류적치료중취득료흔호료효,목전연구최다적시침대B세포림파류표면적CD19항원.문장종술료항CD19 CAR T세포재복발난치B세포림파류중적료효、불량반응급목전존재적문제.
The prognosis of B cell lymphoma has been significantly improved in the rituximab era,but there are also patients who are refractory or relapsed after rituximab-containing treatment.Chimeric antigen receptor T (CAR T) cell is a kind of T cell which is genetically modified to target specific antigen expressed on the lymphoma cell surface.The response rate of CAR T cell in relapsed or refractory B cell lymphoma is inspiring.Anti-CD19 CAR T cell is the most popular cell being tested in clinical studies.This article discussed the present situation of CAR T cell in B cell lymphoma,including the efficacy,toxicity,side effects and open questions existing in this treatment.